Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine radiopharmaceutical candidates. These were developed by Frank Roesch, PhD, and colleagues at the Institute of Nuclear Chemistry at the Johannes Gutenberg-Universität Mainz, Germany.
Telix’s development program will initially focus on the treatment of bladder cancer. FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.
Telix said these new therapeutic assets are differentiated by a structure that drives extended tumor retention while minimizing off-target uptake. The diagnostic and therapeutic compounds have been clinically validated in more than 500 patients across a variety of solid tumors and are the subject of multiple peer-reviewed publications.
